Aspiring to be one of the top 3 Russian pharmaceutical companies producing antibiotics in the next 5 years, the penny stock of Rafarma Pharmaceuticals, Inc. (PINK: RAFA) displayed some massive bullishness on Friday afternoon. Shares of RAFA stock were being bought up on Friday before the close like last minute gifts on Xmas Eve as traders anticipated a sold opening for the pinksheeter come Monday. Having agreed with QualityStocks almost 2 months ago to be featured in The Small Cap QualityStocks Daily Newsletter, it’s nice to finally see the bleeding has temporarily stopped after falling from 0.59.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
RAFA Stock Quote
Market Cap: 9.68M
Last: 0.119 ▲ 0.019 (+19.00%)
Dollar Volume: $69,273
Issued and Outstanding: 81,370,870
14-Day Rel Strength: 42.72%
14-Day Stochastic: 78.79%
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
A manufacturer of generic pharmaceuticals and proprietary medications and the beneficial owner of distributed profits from OOO Rafarma, Rafarma Pharmaceuticals has the sales and distribution rights for all Rafarma products in Central and South America. The Company hopes to be able to develop a strategic alliance with suitable parties in Latin America so they can pull the metaphoric thumb out of their butt so they can actually do something with those rights.
For the last reported quarter, sales equaled cost of sales and all the expenses for the quarter were the exact same amounts from the comparable period the year before. That type of reporting basically says “financials” are not a reliable means for assessing the value RAFA stock should be trading at.
However, if you listen to what Dave Anderson, CEO, and Alexander Ageev, Secretary/Treasurer, want investors to focus on, “Net Present Value” is how one should approach RAFA. Using a combination of value based on sales and value based on cash flow/profits and due to the structure of the investment and the unique capabilities of “OOO Rafarma”, using the 2013 projected earnings of $34K, Rafarma Pharmaceuticals should be valued above $327.73M; the average Health Care, High tech and Manufacturing companies.
I guess if RAFA is going to consider themselves a company worth $327 mllion, then AimHighProfits’ Tina Yi can be considered a super model after her vacation to Boracay last week.
About RAFA Stock
Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to our own line of proprietary products that are approved by the Ministry of Health of the Russian Federation.
Last 5 Trading Sessions:
RAFA stock was a penny stock with fleas up until 2:30PM on Friday when it shot up for nearly a 200% intraday gain. While everyone is trying to get a jump on the next big promo due to come out from TBX, why the heck not watch RAFA pre-market on Monday.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share